Chromosome-damaging action of isoniazid and thiacetazone on human lymphocyte cultures in vivo
β Scribed by Y. R. Ahuja; Madhuri Jaju; Manjula Jaju
- Publisher
- Springer
- Year
- 1981
- Tongue
- English
- Weight
- 187 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0340-6717
No coin nor oath required. For personal study only.
β¦ Synopsis
Antitubercular drugs in general are given in various combinations, one being isoniazid and thiacetazone. In the present study, was evaluated the in vivo chromosome-damaging effects of a combination of these two drugs in 72 h lymphocyte cultures. Chromosome aberrations were significantly increased in the patients treated with INH and thiacetazone as compared with two types of controls: (1) tuberculosis patients before starting the drug treatment and (2) individuals from the general population. The most frequently observed aberrations were chromatid breaks and gaps. It has been shown that individually, isoniazid may not be clastogenic on human chromosomes in therapeutic doses. The effects of thiacetazone on human chromosomes are not known. Consequently, the enhancement in chromosomal aberrations in the drug-exposed patients may be due to a synergistic effect of isoniazid and thiacetazone or to the clastogenic effects of thiacetazone alone.
π SIMILAR VOLUMES
Some chemotherapeutic approaches have proposed the use of antioxidants such as vitamin C (VC) to minimize the cytotoxicity and damage induced in normal tissue by antitumor agents that produce free radicals. Nevertheless, VC can also be cytotoxic, genotoxic, and harmful when combined with antitumor a
Cytogenetic effects of three combinations of anti-tubercular drugs were evaluated on human lymphocytes in vivo and were compared with controls of two types: (1) newly diagnosed tuberculosis patients before starting therapy and (2) individuals from the general population. The drugs used were: isoniaz
In this study the clastogenic effect of pyrimethamine (Daraprim), a folic acid antagonist used for the treatment of toxoplasmosis and malaria on human chromosomes, was investigated. Pyrimethamine was added to in vitro lymphocyte cultures at six different concentrations: 0.05 (normal therapeutic dose